Similar articles for PMID: 26284497

Year	Number of Results
2005	1
2006	1
2008	2
2010	5
2011	7
2012	5
2013	14
2014	16
2015	10
2016	9
2017	9
2018	14
2019	9
2020	6
2021	5
2024	0

1

Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.

Korkut A, Wang W, Demir E, Aksoy BA, Jing X, Molinelli EJ, Babur Ö, Bemis DL, Onur Sumer S, Solit DB, Pratilas CA, Sander C. Korkut A, et al. Elife. 2015 Aug 18;4:e04640. doi: 10.7554/eLife.04640. Elife. 2015. PMID: 26284497 Free PMC article.

2

Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.

Zhou B, Ritt DA, Morrison DK, Der CJ, Cox AD. Zhou B, et al. J Biol Chem. 2016 Aug 19;291(34):17804-15. doi: 10.1074/jbc.M115.712885. Epub 2016 May 17. J Biol Chem. 2016. PMID: 27226552 Free PMC article.

3

Perturbing resistance: a network perspective.

Levesque MP, Dummer R, Beerenwinkel N. Levesque MP, et al. Pigment Cell Melanoma Res. 2016 Jan;29(1):5-7. doi: 10.1111/pcmr.12431. Pigment Cell Melanoma Res. 2016. PMID: 26471867 No abstract available.

4

An integrated framework for identification of effective and synergistic anti-cancer drug combinations.

Sharma A, Rani R. Sharma A, et al. J Bioinform Comput Biol. 2018 Oct;16(5):1850017. doi: 10.1142/S0219720018500178. Epub 2018 Jun 28. J Bioinform Comput Biol. 2018. PMID: 30304987

5

Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.

Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S. Nakamura A, et al. Cancer Res. 2013 Dec 1;73(23):7043-55. doi: 10.1158/0008-5472.CAN-13-1825. Epub 2013 Oct 11. Cancer Res. 2013. PMID: 24121489

6

A Computational Approach for Identifying Synergistic Drug Combinations.

Gayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O. Gayvert KM, et al. PLoS Comput Biol. 2017 Jan 13;13(1):e1005308. doi: 10.1371/journal.pcbi.1005308. eCollection 2017 Jan. PLoS Comput Biol. 2017. PMID: 28085880 Free PMC article.

7

Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.

Chen J, Shen Q, Labow M, Gaither LA. Chen J, et al. Cancer Res. 2011 Jun 15;71(12):4280-91. doi: 10.1158/0008-5472.CAN-10-3761. Epub 2011 Apr 28. Cancer Res. 2011. PMID: 21527556

8

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.

Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C. Cesi G, et al. Mol Cancer. 2017 Jun 8;16(1):102. doi: 10.1186/s12943-017-0667-y. Mol Cancer. 2017. PMID: 28595656 Free PMC article.

9

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.

Wang AX, Qi XY. Wang AX, et al. IUBMB Life. 2013 Sep;65(9):748-58. doi: 10.1002/iub.1193. Epub 2013 Jul 29. IUBMB Life. 2013. PMID: 23893853 Free article. Review.

10

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA. Wagle N, et al. Cancer Discov. 2014 Jan;4(1):61-8. doi: 10.1158/2159-8290.CD-13-0631. Epub 2013 Nov 21. Cancer Discov. 2014. PMID: 24265154 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year